key: cord-0985270-39etymd1
authors: Sullivan, Kelly Daniel; Galbraith, Matthew Dominic; Kinning, Kohl Thomas; Bartsch, Kyle William; Levinsky, Nik Caldwell; Araya, Paula; Smith, Keith Patrick; Granrath, Ross Erich; Shaw, Jessica Rose; Baxter, Ryan Michael; Jordan, Kimberly Rae; Russell, Seth Aaron; Dzieciatkowska, Monika Ewa; Reisz, Julie Ann; Gamboni, Fabia; Cendali, Francesca Isabelle; Ghosh, Tusharkanti; Monte, Andrew Albert; Bennett, Tellen Demeke; Miller, Michael George; Wen-Yuan Hsieh, Elena; D’Alessandro, Angelo; Hansen, Kirk Charles; Espinosa, Joaquin Maximiliano
title: The COVIDome Explorer Researcher Portal
date: 2021-07-28
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109527
sha: b384bc3e52b24616c680d9606ac8d774b27f0bac
doc_id: 985270
cord_uid: 39etymd1

COVID-19 pathology involves dysregulation of diverse molecular, cellular, and physiological processes. To expedite integrated and collaborative COVID-19 research, we completed multi-omics analysis of hospitalized COVID-19 patients including matched analysis of the whole blood transcriptome, plasma proteomics with two complementary platforms, cytokine profiling, plasma and red blood cell metabolomics, deep immune cell phenotyping by mass cytometry, and clinical data annotation. We refer to this multidimensional dataset as the COVIDome. We then created the COVIDome Explorer, an online researcher portal where the data can be analyzed and visualized in real-time. We illustrate here the use of the COVIDome dataset through a multi-omics analysis of biosignatures associated with C-reactive protein (CRP), an established marker of poor prognosis in COVID-19, revealing associations between CRP levels and damage-associated molecular patterns, depletion of protective serpins, and mitochondrial metabolism dysregulation. We expect that the COVIDome Explorer will rapidly accelerate data sharing, hypothesis testing, and discoveries worldwide.

Throughout the course of the COVID-19 pandemic, researchers around the world have made significant progress in the understanding of diverse aspects of the condition, including the epidemiology of SARS-CoV-2 infection and the underlying molecular, cellular, and physiological processes dysregulated in COVID-19 patients. This included completion of sophisticated genetic, molecular, and cellular analyses, as well as launching of myriad clinical trials. In many instances the rapid pace of discoveries has been facilitated by the assembly of large collaborations. Another factor accelerating the pace of research is the widespread use of pre-print collections where papers under peer-review can be accessed freely ahead of publication. However, we posit that the speed of research is being hampered by the lack of widely accessible, analysis-ready public datasets that could be analyzed in real-time by experts and non-experts alike. Although great progress has been made in publication policy in terms of ensuring that the data fueling published discoveries are made accessible through public data repositories, most datasets remain inaccessible to broad audiences and can be downloaded and reanalyzed only by experts. To further accelerate research at a global scale, we created a multidimensional dataset derived from hospitalized COVID-19 patients versus COVID-19-negative controls, known as the COVIDome dataset, and made it readily accessible through a user-friendly platform, the COVIDome Explorer researcher portal.

The COVIDome dataset includes demographics and clinical data, along with matched analysis of the whole blood transcriptome via RNAseq (measuring 16,000+ RNAs), analysis of the plasma proteome by complementary SOMAscan® assays (measuring 4800+ epitopes), mass spectrometry (400+ abundant proteins), and multiplexed cytokine profiling (80+ immune modulatory factors), analysis of the plasma and red blood cell metabolomes by mass spectrometry, deep immune phenotyping by mass cytometry (measuring 100+ immune cell types), and seroconversion assays. All datasets are publicly accessible through a user-friendly, analysis-ready researcher portal dubbed the COVIDome Explorer (www.covidome.org). In this manuscript, we describe how the datasets were generated and analyzed, and explain how to use the COVIDome Explorer for rapid hypotheses testing, hypothesis generation, and real-time discoveries by experts and non-experts. We illustrate the prowess of the COVIDome J o u r n a l P r e -p r o o f 6

In order to investigate variations in the endotype of COVID-19 patients, we completed a multi-omics assessment of 105 research participants, including 73 hospitalized COVID-19 patients versus 32 COVID-19-negative controls ( Figure 1A) . The demographics and clinical characteristics of this cohort are described in Supp. File 1. All COVID-19-positive participants were hospitalized due to moderate symptoms, but none had developed severe clinical disease requiring ICU admission at the time of blood collection. Of note, some annotated comorbidities were more prevalent in the control group; however, the available clinical data do not distinguish between 'history of' and 'present at admission', somewhat limiting the interpretation of these data. COVID-19 positivity was defined from results of PCR and/or antibody testing within 14 days of the research blood draw (see Methods). Blood samples were analyzed by a matched multi-omics assessment of the transcriptome via RNAseq of whole blood, plasma proteomics using two alternative platforms [mass spectrometry (MS) and SOMAscan ® ], cytokine profiling using multiplexed immunoassays for 80+ immune factors using Meso Scale Discovery (MSD) assays, plasma and red blood cell (RBC) metabolomics via mass spectrometry, immune cell phenotyping via mass cytometry (MC), and seroconversion assays for detection of antibodies against SARS-CoV-2 nucleocapsid and spike polypeptides ( Figure 1A) . Importantly, all datasets were generated from different fractions of the same blood draw from each research participant, enabling effective cross-platform analyses.

To generate the transcriptome dataset, whole blood was collected in PAXgene RNA tubes, RNA extracted and subjected to next generation sequencing (see Methods). Analysis of the transcriptome dataset using DESeq2 (Love et al., 2014) identified 2299 differentially expressed genes (DEGs) in the bloodstream of the COVID-19 patients ( Figure 1B) . Examples of significantly upregulated DEGs include specific immunoglobulin sequences (e.g., , indicative of seroconversion, as well as interferon-stimulated genes (ISGs) (e.g., MX1), indicative of an antiviral transcriptional response. An interactive volcano plot similar to that in Figure 1B To generate the SOMAscan® proteomics dataset, plasma was analyzed with SOMAmer ® technology to measure the abundance of 4800+ epitopes corresponding to 3000+ unique proteins (see Methods). Using a linear model adjusting for age and sex, we identified 970 differentially abundant epitopes in the plasma of COVID-19 patients ( Figure 1C) . Examples of significantly upregulated proteins include many ISGs, such as ISG15 and IFIT3 (Interferon Induced Protein with Tetratricopeptide Repeats 3) ( Figure   1C ). To generate the MS proteomics dataset, the same plasma aliquot used for SOMAscan ® proteomics was analyzed by MS (see Methods). This approach enabled the quantification of 412 abundant proteins in plasma ( Figure 1D ). The MS proteomics dataset is highly complementary to the SOMAscan ® proteomics dataset, as it enables detection of many abundant proteins for which SOMAmer ® reagents are not available. For example, analysis of the MS proteomics dataset using a linear model adjusting for age and sex identified 74 differentially abundant proteins, including clear upregulation of immunoglobulin sequences not detected by the SOMAscan ® but which were also detected as upregulated in the transcriptome dataset (e.g., IGHV1-24, IGLV3-1) ( Figure 1D ).

Interactive volcano plots and box and whisker plots for the two proteomics datasets can be generated in the Proteome dashboard of the COVIDome Explorer at: https://covidome.shinyapps.io/Proteome/.

Results of the linear models described here can be found in Supp. File 2B (SOMAscan ® proteomics) and Supp. File 2C (MS proteomics) .

To generate the cytokine profile dataset, the same aliquot of plasma used for the proteomics analyses was employed to measure the levels of a select list of immune modulatory factors via multiplexed immunoassays using MSD assays. A linear model adjusting for age and sex revealed many cytokines differentially abundant in the bloodstream of COVID-19 patients, such as CXCL10 (C-X-C motif chemokine ligand 10, interferon-inducible protein 10, IP10) and IL10 (Interleukin 10) ( Figure 1E ).

Interactive volcano plots and box and whisker plots for this dataset can be generated in the Cytokine dashboard of the COVIDome Explorer at: https://covidome.shinyapps.io/Cytokines/. Results of the linear model for MSD data can be found in Supp. File 2D.

J o u r n a l P r e -p r o o f 8 To investigate metabolic dysregulation in COVID-19, we completed parallel targeted analyses of the RBC and plasma metabolomes using ultra-high pressure liquid chromatography coupled to mass spectrometry (UHPLC-MS) (see Methods). RBC and plasma metabolomic signatures inform about different metabolic and physiological processes, with both common and unique metabolites measured in each matrix. Analysis of the RBC metabolome revealed 35 differentially abundant metabolites in COVID-19 patients, such as upregulation of kynurenine, a sign of activation of the IFN-inducible kynurenine pathway of tryptophan catabolism (Thomas et al., 2020) , and xanthine, a sign of dysregulated purine metabolism ( Figure 1F ). Identical analysis of the plasma metabolome revealed many differentially abundant metabolites in COVID-19 patients, including kynurenine and xanthine as well ( Figure S1 ). Interactive volcano plots and box and whisker plots for the two metabolomics datasets can be generated in the Metabolome dashboard of the COVIDome Explorer at: https://covidome.shinyapps.io/Metabolome/. Results of the linear models for metabolomics can be found in Supp. File 2E (RBC metabolomics) and Supp. File 2F (Plasma metabolomics).

Lastly, we completed a comprehensive map of peripheral immune cell lineages using MC, which enabled the identification and curation of 100+ immune cell subsets (see Methods). Toward this end, we utilized peripheral blood mononuclear cells (PBMCs) purified by Ficoll gradient from the same blood draw used for all other datasets and stained them with a panel of 40 metal-coupled antibodies designed to quantify many major and minor lymphoid and myeloid subsets (see Methods). In order to quantify differences in immune cell subsets within their parent lineage, we created 7 different immune maps, stemming from: 1) all live cells, 2) CD3+ T cells (all T cells), 3) CD4+ T cells, 4) CD8+ T cells, 5) CD19+ B cells, 6) CD11c+ monocytes (CD3-CD19-CD56-), and 7) CD1c+ myeloid dendritic cells (mDCs) (CD3-CD19-CD56-). Using a linear model adjusting for age and sex, we identified many immune cell types with significantly different frequency among all live cells in COVID-19-positive patients, such as increased frequencies of plasmablasts and decreased frequencies of CD1c+ mDCs ( Figure 1G ).

Interactive volcano plots and box and whisker plots for the 7 immune maps can be generated in the Immune Maps dashboard of the COVIDome Explorer at: https://covidome.shinyapps.io/ImmuneMaps/.

Results of the linear models for each immune lineage can be found in Supp. File 2G-M.

In sum, the COVIDome dataset includes major data types for the study of diverse biological processes dysregulated in hospitalized COVID-19 patients.

To facilitate quick and broad access to the COVIDome dataset, we created a user-friendly online portal, dubbed the COVIDome Explorer, which can be accessed online at covidome.org (see overview in After data curation and quality control, each of the COVIDome datasets was linked at the sample level with a unique identifier, enabling cross-referencing among platforms. Then each of the datasets were imported into applications developed using R, R Studio, and the R-based web application framework Shiny. Each application includes custom-developed features that enable rapid query, visualization, and download of data, in an interactive environment (see Methods). The COVIDome Explorer hosts six dashboards: Cohort, Transcriptome, Proteome, Cytokines, Metabolome, and Immune Maps. Each dashboard runs within its own isolated and protected environment, hosted on the cloud-based Platformas-a-Service (PaaS) environment "shinyapps.io." When a user navigates to a specific dashboard via URL, individual instances of the Shiny application are instantly deployed to the shinyapps.io hosting platform, allowing for interaction and analysis throughout the duration of the user's session. The Cohort dashboard is a simple description of the research cohort involved. The other dashboards are organized in a similar fashion and present similar options for analysis. This similarity allows users to become familiar with one dashboard, and then rapidly adapt to the use of the other dashboards. Each the five analytical dashboards contains four tabs: Overview, Effect of COVID-19 status, Effect of Seroconversion, and Cross Omics Correlates. The Overview tab provides a summary of the approach, a brief explanation on how to use the dashboards, and in some instances, links to data files that would guide users, such as catalogs of proteins, metabolites, cytokines and immune cells present in each dataset. The Overview tab also points to publications that provide further detail about the methodology employed. The 'Effect of COVID-19 status' tab enables users to investigate differences between the COVID-19-negative control cohort and COVID-19-positive patients. The 'Effect of Seroconversion' tab J o u r n a l P r e -p r o o f 10 enables users to investigate differences among COVID-19 patients with low versus high titers of anti-SARS-CoV-2 antibodies. A detailed description of the metrics of seroconversion employed and the definition of 'sero-low' versus 'sero-high' groups can be found in a recent publication illuminating how seroconversion stages COVID-19 into distinct pathophysiological states (Galbraith et al., 2021) .

Upon entry into a given dashboard, users must select from a menu of options before data can be displayed. For the Proteome and Metabolome dashboards the first option is the choice of Platform: [None, Bonferroni, Benjamini-Hochberg (false discovery rate, FDR)]. Users with a pre-formed hypothesis in mind interested in searching for a specific feature of interest (e.g., specific mRNA, protein, or immune cell type) may opt out of a multiple hypothesis adjustment method. In contrast, users exploring the data in an unbiased fashion should select an adjustment method to account for multiple hypotheses testing. Two other filters are sex (both, Male, Female) and Age (All, 21 & Over), which enable users to visualize all or a fraction of the dataset. At this stage, users can 'Apply filters and generate plot', which would then lead to the appearance of an interactive volcano plot displaying the results. Users can then 'mouse over and click' individual features in the volcano plot to display a box and whisker plot for that specific feature. Alternatively, users can use the searchable menus to find a feature of interest. Once an individual feature has been selected, live links to external databases become available, including PubMed, GeneCards, GTEx, NCBI and Wikipedia, thus allowing users to navigate away from the COVIDome Explorer and learn more about a gene, protein, cytokine, metabolite, or immune cell type of interest. Of note, both volcano plots and box and whisker plots can

In each dashboard, the data being visualized can be accessed through the 'Aggregated Data' or 'Sample Level Data' tabs, two distinct interactive spreadsheets. In these tabs, users can filter by fold J o u r n a l P r e -p r o o f 11 change and p-value, sort by any of the columns visible (e.g., gene/protein name, fold change, p-value), and search for individual features. Users can then download the data as comma-separated values file (.csv), Microsoft Excel spreadsheet (.xlsx), or pdf files.

Altogether, the COVIDome Explorer dashboards enable data access and analysis by a broad range of users with different degrees of bioinformatics and biostatistics literacy, from those simply interested in a group comparison for a single protein, to those interested in sophisticated off-line analyses of the downloaded datasets.

To enable cross-platform discoveries, we created a 'Cross Omics Correlates' tab in each dashboard that allows users to explore relationships among features both within and across COVIDome datasets for COVID-19-positive patients. To examine connections among features, the 'Cross Omics Correlates' dashboard performs Spearman Correlations using age-and sex-adjusted data. When a user accesses the Cross Omics Correlates tab, they navigate to a landing page with numbered instructions for use on the left as well as a 'Take Tutorial' option. First, the user selects a query platform when applicable (e.g., Mass spectrometry Proteome vs. SOMAscan ® Proteome); second, the user selects a query feature; third, the user selects a comparison platform; and fourth, the user clicks the 'Generate Volcano Plot' button. This renders a volcano plot with correlation data for all features in the comparison platform versus the query feature, where Spearman rho values are represented along the x-axis and Benjamini-Hochberg adjusted q-values along the y-axis. An optional fifth step allows users to visualize XY scatter plots for analyte pairs of interest. For example, the mRNA encoding the viral restriction factor MX1, which is upregulated in the whole blood transcriptome of COVID-19 positive individuals (Figure 1B) , is strongly correlated with many plasma proteins measured by SOMAscan ® (Figure 3A) . Among the most positively correlated proteins are numerous other ISGs including CXCL10 and IFIT3 ( Figure 3A) . MX1 protein is also strongly correlated with MX1 mRNA levels ( Figure 3A-B) . This same method can be applied to any other pairwise cross-omics comparison. For instance, levels of the metabolite kynurenine in RBCs are positively correlated with plasma levels of WARS (tryptophanyl-tRNA synthetase 1) and J o u r n a l P r e -p r o o f 12 NADK (nicotinamide adenine dinucleotide kinase), two enzymes involved in tryptophan metabolism ( Figure 3C-D) . WARS is an ISG that may be upregulated as a compensatory mechanism for kynurenine pathway-mediated tryptophan depletion (Sarkar et al., 2007 , Adam et al., 2018 , and NADK is a kinase that converts NAD+ produced by the kynurenine pathway into NAD phosphate (NADP) (Castro-Portuguez and Sutphin, 2020). The 'Cross Omics Correlates' can also be used to compare immune cell subsets with gene expression data. For example, plasmablasts, which are among the most upregulated immune cells in COVID-19-positive individuals, are positively correlated with many immunoglobulin genes in the whole blood transcriptome, such as IGKV4-1, IGHV6-1, and IGLC2, indicative of B cell differentiation toward plasmablasts producing specific immunoglobulin sequences targeting SARS-CoV-2 ( Figure 3E-F) . These examples demonstrate the ability of the COVIDome dataset, in concert with the COVIDome Explorer, to reveal potentially biologically meaningful relationships among features across diverse -omics datasets.

To illustrate the utility of the matched multidimensional COVIDome datasets, we analyzed multi-omics biosignatures associated with varying levels of CRP, an acute phase protein whose elevation in circulation has been consistently associated with poor prognosis in COVID-19. Repeatedly, higher CRP levels at the time of hospitalization and/or rapid rise in CRP levels during hospitalization have been associated with increased probability of developing severe COVID-19 pathophysiology (Mousavi-Nasab et al., 2020 , Mueller et al., 2020 , Sharifpour et al., 2020 . As expected, CRP is also elevated in our cohort of COVID-19 patients as measured by MS proteomics, as well as other acute phase proteins such as ferritin (FTL) (Figure 4A ). To identify biosignatures associated with CRP levels among COVID-19-positive patients, we calculated Spearman correlations between CRP values measured by MS and all features in all COVIDome datasets, which revealed myriad mRNAs, proteins, and metabolites significantly associated with CRP levels (Figure S2A Molecular Patterns (DAMP) molecules whose presence in the bloodstream is consistently associated with tissue damage and trauma, and which in turn function as ligands for amplification of innate immune signaling (Huang et al., 2011) . Circulating histones can be released from dying cells in the liver and they have been shown to drive downstream damage to both pulmonary and hepatic endothelial cells (Kawai et al., 2016) . Histones in the bloodstream could also be interpreted as a sign of netosis and formation of neutrophil extracellular traps (NETS) (Papayannopoulos, 2018) . HSPs have also been . In fact, the most positively correlated mRNA is H2BC12, one of the H2B-encoding genes, and the fifth most correlated gene is H2AC19, one of the H2A-encoding genes, both elevated in the whole blood transcriptome of COVID-19-positive patients ( Figure S2I) . Given that the mRNAs captured in this transcriptome analysis are derived from circulating immune cells and that histone mRNAs are transcribed during the S phase of the cell cycle, this could be interpreted as a sign of stronger immune cell activation and proliferation in patients with higher CRP levels.

Altogether, these results indicate that high CRP levels in COVID-19 associate not only with activation of inflammatory pathways, but also with elevated DAMPs, indicative of tissue damage.

Analysis of the proteins negatively correlated with CRP levels revealed that in both proteomics datasets the most anti-correlated proteins are SERPINA5 (Protein C Inhibitor, PCI, Plasminogen Activator Inhibitor 3, PAI3) and SERPINA4 (Kallistatin), two members of the serpin family of serine protease inhibitors ( Figure 5A -B, Figure S2B -C, Figure S3 , Supp. Files 3B,C). Both SERPINA5 and SERPINA4 play protective roles during vascular and organ injury (Chao et al., 2016 , Suzuki, 2008 , but the mechanisms driving these protective effects remain to be elucidated. SERPINA5 is a multifunctional serpin that can act as both a procoagulant via inhibition of activated protein C and thrombin, but also as an anticoagulant by inhibiting several coagulation factors including plasma kallikrein (KLKB1, kallikrein B1) (Meijers et al., 1988) , tissue kallikreins (Ecke et al., 1992) , prothrombin, and factors XI and Xa, among others (Suzuki, 2008) . SERPINA4/Kallistatin is a potent inhibitor of tissue-specific kallikreins (KLKs) (Chao et al., 2016) . Notably, both of these serpins converge on inhibition of KLKs, a family of serine proteases involved not only in control of coagulation and fibrinolysis, but also production of vasoactive kinin peptides, such as bradykinin, as well as activation of the complement cascade (Irmscher et al., 2018, Ricklin and Lambris, 2007) . Therefore, we investigated if CRP levels correlated significantly with dysregulation of components of the interconnected coagulation and complement Altogether, these results indicated that the prognostic value of high CRP levels in COVID-19 could be potentially tied to the accompanying depletion of important protective serpins and consequent dysregulation of the coagulation, fibrinolysis, and complement cascades, both of which have been involved in the etiology of severe COVID-19 pathology (Lo et al., 2020) .

Next, we investigated associations between CRP levels and metabolic changes detected in the plasma and RBC metabolomics datasets ( Figure S2E Lactate, which can be oxidized to pyruvate by lactate dehydrogenase, was also positively correlated with CRP ( Figure 6A ). Increases in lactate and pyruvate can be interpreted as increased glycolysis in patients with high CRP, perhaps driven by hypoxia leading to carbon flow from pyruvate to acetyl-CoA. Increased glycolysis is a metabolic consequence of both immune cell activation and hypoxemia (Makowski et al., 2020 , Frauwirth et al., 2002 , Michalek et al., 2011 , Jellusova, 2020 , van Teijlingen Bakker and Pearce, 2020 . Importantly, each of these three classes of metabolites represent entry points to the TCA cycle and elevated levels of these features are consistent with mitochondrial dysfunction and decreased activity in the TCA cycle and the electron transport chain (ETC).

Given that these metabolic associations between CRP and plasma metabolites could be due to metabolic dysregulation in peripheral blood cells and/or various host tissues, we asked if these J o u r n a l P r e -p r o o f 16 associations could be explained by gene expression changes in circulating blood cells by analyzing the whole blood transcriptome dataset. We used the Ingenuity Pathway Analysis (IPA) software to identify gene sets enriched among the RNAs positively and negatively correlated with CRP, with a focus on metabolic pathways. Strikingly, the most significantly enriched metabolic pathway among negatively correlated mRNAs is Oxidative Phosphorylation (OXPHOS) (Figure 6B , see Figure S4A for positively correlated gene sets). The OXPHOS gene signature is comprised of 54 genes including many components of the ETC, such as NADH:ubiquinone oxidoreductase subunits, cytochrome C complex subunits, and ATP synthase subunits, among others ( Figure 6C ). For example, expression of NDUFV3 (NADH:Ubiquinone Oxidoreductase Subunit V3, Complex I, Mitochondrial Respiratory Chain, 10-KD Subunit) and COX4I1 (Cytochrome C Oxidase Subunit 4I1) are both negatively correlated with CRP levels and significantly decreased in COVID-19 patients, as is the Mitochondrially Encoded Cytochrome C Oxidase III (MT-CO3) ( Figure 6D) . Therefore, accumulation of TCA carbon sources in plasma could be linked to decreased gene expression of ETC components in circulating blood cells. Interestingly, we noticed that the mRNAs encoding the glucose transporter SLC2A3 (GLUT3) and the monocarboxylate transporter SLC16A3 (monocarboxylate transporter 4, MCT4), were both positively and significantly correlated with CRP in the whole blood transcriptome of COVID-19 patients ( Figure S4B ). Increases in surface expression of SLC2A3 have been noted during activation of diverse lymphocytes, neutrophils and platelets, and thought to mediate increased glucose uptake to fuel cell activation (Simpson et al., 2008) . SLC16A3 catalyzes the bidirectional transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, as well as branched-chain oxo-acids derived from leucine, valine, and isoleucine. In innate immune cells, lactate is produced and exported in large amounts via SLC16A3 during pro-inflammatory responses and its expression is upregulated in activated macrophages (Weiss and Angiari, 2020) . Furthermore, SLC16A3 expression is necessary for macrophage activation, as its deletion results in intracellular accumulation of lactate and decreased glycolysis (Weiss and Angiari, 2020) .

Altogether, the metabolic changes associated with CRP could be understood, in part, as the byproduct of metabolic remodeling of circulating blood cells, whereby decreased expression of OXPHOS genes J o u r n a l P r e -p r o o f 17 and increased expression of glucose and monocarboxylate transporters would lead to increased glucose uptake, decreased OXPHOS, and consequent accumulation of glycolysis end products (lactate, pyruvate) and other carbon sources for the TCA cycle (branched chain amino acids, acyl carnitines).

J o u r n a l P r e -p r o o f 18

The global health crisis imposed by the COVID-19 pandemic has inspired new approaches for rapid collaboration, open access to manuscripts under review, and data sharing. Here, we describe the rapid creation of a user-friendly researcher portal enabling easy access and real-time analysis of matched multi-omics datasets for COVID-19. The first batch of biospecimens for the COVIDome project was received by this team in July 2020, and the COVIDome Explorer was publicly launched in November 2020, thus spanning only five months from sample processing to portal launch. Between November 2020 and June 2021, more than 800 unique users from 36 countries had utilized the portal according to session data gathered from Google Analytics. Currently, the second batch of samples is being subjected to identical multi-omics analyses. Importantly, the COVIDome Explorer can easily ingest datasets from other teams to be displayed in its dashboards, which would then enable the comparison of results across different studies.

With the advent of multi-omics platforms, it is now possible to rapidly investigate hundreds of molecular, cellular, and physiological processes from a single biospecimen. Such a systems biology approach enables the integration of findings across different methodologies and layers of biological information to expedite the pace of discovery into the etiology of a medical condition. In this report, we illustrate the power of this approach by exploring biosignatures associated with CRP, a well characterized marker of inflammation across numerous medical conditions, including COVID-19. Although it is well established that CRP levels and trajectory have prognostic value in COVID-19 (Mousavi-Nasab et al., 2020 , Mueller et al., 2020 , Sharifpour et al., 2020 , the exact pathophysiological processes associated with this clinical biomarker of inflammation remain to be fully elucidated. What exactly is being revealed by high baseline levels and/or rapid elevation of CRP in COVID-19? Our analysis demonstrates that, in addition to the well-established links between CRP and other markers of inflammation and immune activity, CRP levels associate with DAMPs, depletion of protective serpins, and dysregulation of mitochondrial metabolism in blood cells in COVID-19.

The association between CRP and DAMPs reveals that CRP levels inform about the extent of tissue damage in COVID-19. High levels of CRP associate with increased circulating levels of intracellular J o u r n a l P r e -p r o o f 19 proteins released into the bloodstream during organ damage (e.g., histones, HSPs), which can further exacerbate the inflammatory phenotype. In turn, increased tissue damage could be conceptually tied to the clear depletion of the protective serpins SERPINA4 and SERPINA5, the most anti-correlated proteins with CRP in our proteomics datasets. SERPINA4/5 depletion could lead to exacerbated, harmful levels of activity within the coagulation system, kallikrein-kinin system, and complement cascade, all of which can contribute to COVID-19 pathology. Depletion of SERPINA5 could unleash a protease storm within the coagulation cascade, leading to coagulopathies and thromboembolism in COVID-19 (Becker, 2020) . Given that both SERPINA4 and SERPINA5 inhibit KLKs, the serine proteases driving production of the vasoactive peptide bradykinin, their depletion could contribute to the so called 'bradykinin storm' in COVID-19 linked to accumulation of fluids in the lungs and respiratory failure (Garvin et al., 2020) . Lastly, since KLKs also activate the complement cascade, SERPINA4/5 depletion could lead to harmfully high levels of complement activity and consequent tissue damage by the membrane attack complex (MAC). Of note, all these processes are suitable to pharmacological modulation and the focus of many ongoing clinical trials testing the efficacy of blood thinners (Rentsch et al., 2021) , kinin receptor antagonists (van de Veerdonk et al., 2020) , and complement inhibitors (Mastellos et al., 2021) in COVID-19. Therefore, we posit that CRP could serve as a biomarker to stratify the patient cohorts in these clinical trials to assess potential differences between individuals with varying CRP levels. We also hypothesize that SERPINA4 and/or SERPINA5 administration could be a valid therapeutic strategy in COVID-19 to reduce organ damage, especially in patients with high CRP levels (Rau et al., 2007 , Suzuki, 2008 .

Interpretation of the association between CRP levels and markers of dysregulated mitochondrial metabolism must consider a combination of metabolic effects on circulating blood cells and host tissues. Plasma metabolomics can inform about metabolic alterations in the peripheral immune cell repertoire, platelets and RBCs, but also about dysregulated metabolism in various organs. CRP levels correlated with increased levels of three different carbon sources for the TCA cycle: branched chain amino acids (leucine, isoleucine), end products of glycolysis (lactate, pyruvate), and acyl carnitines, all of which could be explained by decreased activity in the TCA cycle and ETC. Indeed, when analyzing J o u r n a l P r e -p r o o f 20 the transcriptome of circulating immune cells, the top gene signature negatively associated with CRP was OXPHOS, with expression of many components of the ETC being downregulated in patients with high CRP. Furthermore, these changes were accompanied by increased mRNA expression of the glucose transporter SLC2A3 and the monocarboxylate transporter SLC16A3, which can be associated to activation of different immune cell subsets Angiari, 2020, Simpson et al., 2008) .

Dysregulation of mitochondrial metabolism is increasingly appreciated in COVID-19 (Burtscher et al., 2020) . Notably, disruption of the TCA cycle has been reported downstream of inflammatory stimulation via a mechanism shunting citrate to succinate driving additional inflammation, largely in myeloid cells (Tannahill et al., 2013 , Mills et al., 2016 , Makowski et al., 2020 . Importantly, downregulation of OXPHOS and ETC genes has been demonstrated in the liver in the case of hepatitis C infection (Gerresheim et al., 2019) , and in the diaphragm, liver, and peripheral blood during sepsis (Callahan and Supinski, 2005 , Weiss et al., 2014 , Eyenga et al., 2014 .

In sum, the COVIDome datasets and the COVIDome Explorer facilitate rapid hypothesis generation and testing, revealing unexpected associations between diverse molecular, cellular, and pathophysiological processes in COVID-19, even for well-studied factors such as CRP.

J o u r n a l P r e -p r o o f 21

We worked to ensure gender balance in the recruitment of human subjects. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community. One or more of the authors of this paper received support from a program designed to increase minority representation in science. 

Further information and requests for resources and reagents should be directed and will be fulfilled by the Lead Contact, Joaquin Espinosa (joaquin.espinosa@cuanschutz.edu).

This study did not generate new unique reagents.

All data generated for this manuscript is made available through the online researcher gateway of the COVIDome Project, known as the COVIDome Explorer, which can be accessed at covidome.org. The Plasma proteomics by SOMAscan ® assays. 125 L EDTA plasma was analyzed by SOMAscan ® assays using previously established protocols (Gold et al., 2012) . Briefly, each of the 4800+ SOMAmer ® reagents binds a target peptide and is quantified on a custom Agilent hybridization chip.

Specification Technical Note (SSM-020) (Gold et al., 2012) . The output of the SOMAscan ® assay is reported in relative fluorescent units (RFU). To make all samples comparable, pre-processing of mass cytometry data included normalization within and between batches via polystyrene beads embedded with lanthanides as previously described (Finck et al., 2013) . Files were debarcoded using the Matlab DebarcoderTool (Zunder et al., 2015) . Then normalization again between batches relative to a reference batch based on technical replicates (Schuyler et al., 2019) . Gating was performed using CellEngine (Primitybio) as previously described (Galbraith et al., 2021) .

Sample extraction. Samples were thawed on ice and extracted via a modified Folch method (chloroform/methanol/water 8:4:3), which completely inactivates other coronaviruses, such as MERS-CoV. Briefly, 20 μL of sample was diluted in 130 μL of LC-MS grade water, 600 μL of ice-cold chloroform/methanol (2:1) was added, and the samples were vortexed for 10 seconds. Samples were then incubated at 4°C for 5 minutes, quickly vortexed (5 seconds), and centrifuged at 14,000 g for 10 minutes at 4°C. The top (i.e., aqueous) phase was transferred to a new tube for metabolomics analysis and flash frozen. The bottom (i.e., organic) phase was transferred to a new tube for lipidomics analysis, then dried under N 2 flow.

UHPLC-MS metabolomics. Analyses were performed using a Vanquish UHPLC coupled online to a Q Exactive high resolution mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Samples (10 uL per injection) were randomized and analyzed in positive and negative electrospray ionization modes (separate runs) using a 5-minute C18 gradient on a Kinetex C18 column (Phenomenex) as J o u r n a l P r e -p r o o f 34 described (Nemkov et al., 2019) . Data were analyzed using Maven (Princeton University, Princeton, NJ, USA) in conjunction with the KEGG database and an in-house standard library.

Preprocessing, statistical analysis, and plot generation for all datasets was carried out using R (R 4.0.1 / Rstudio 1.3.959 / Bioconductor v 3.11) , R Core Team, 2020 , RStudio Team, 2020 , as detailed below.

Analysis of transcriptome data. RNAseq data yield was ~40-80 x 10 6 raw reads and ~32-71 x 10 6 final mapped reads per sample. Reads were demultiplexed and converted to fastq format using bcl2fastq (bcl2fastq v2.20.0.422). Data quality was assessed using FASTQC (v0.11.5) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and FastQ Screen (v0.11.0, https://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/). Trimming and filtering of low-quality reads was performed using bbduk from BBTools (v37.99) (Bushnell et al., 2017) and fastq-mcf from eautils (v1.05, https://expressionanalysis.github.io/ea-utils/). Alignment to the human reference genome (GRCh38) was carried out using HISAT2 (v2.1.0) (Kim et al., 2019) in paired, spliced-alignment mode with a GRCh38 index with a Gencode v33 annotation GTF, and alignments were sorted and filtered for mapping quality (MAPQ > 10) using Samtools (v1.5) (Li et al., 2009) . Gene-level count data were quantified using HTSeq-count (v0.6.1) with the following options (--stranded=reverse -minaqual=10 -type=exon --mode=intersection-nonempty) using a Gencode v33 GTF annotation file. Differential gene expression in COVID-19-positive versus COVID-19-negative was evaluated using DESeq2 (version 1.28.1) (Love et al., 2014) in R (version 4.0.1), using q < 0.1 (FDR < 10%) as the threshold for differentially expressed genes. SOMAscan ® data. Normalized data (RFU) was imported and converted from a SOMAscan ® .adat file using a custom R package (SomaDataIO) for use in all subsequent analysis.

Analysis of MSD cytokine profiling data. Plasma concentration values (pg/mL) for each of the cytokines and related immune factors measured across multiple MSD assay plates was imported to R, combined, and analytes with >10% of values outside of detection or fit curve range flagged. For each analyte, missing values were replaced with either the minimum (if below fit curve range) or maximum (if above fit curve range) calculated concentration and means of duplicate wells used in all further analysis.

Analysis of LCMS-metabolomics data. Peak intensity data was imported to R. Across the 171 metabolites, 0 values (486 missing values of 21,033 total measurements) were replaced with a random value sampled from between 0 and 0.5x the minimum non-zero intensity value for that metabolite. Data was then normalized using a scaling factor derived from the global median intensity value across all proteins / sample median intensity and used for downstream analysis. This normalization method has been widely employed for MS data, including on the MetaboAnalyst platform (Chong et al., 2019) , and performs comparably to a number of other normalization methods (Valikangas et al., 2018) .

Analysis of mass cytometry data. Cell population frequencies were exported from CellEngine as percentages of various parental lineages and used for subsequent analysis.

Differential abundance analysis. Differential abundance analysis for MS proteomics, SOMAscan ® proteomics, MSD cytokine profiling, LCMS metabolomics, and mass cytometry data was performed using linear models with log 2 concentration as the outcome variable and age, sex, and COVID-19 status as independent variables. Multiple hypothesis correction was performed with the Benjamini-Hochberg method using a false discovery rate (FDR) threshold of 10% (q<0.1). points colored by local density were generated using a custom density function and the ggplot2 (v3.3.1) package (Wickham, 2016) .

Data Visualization. To visualize differences between COVID-19-negative samples and COVID-19positive samples, Z-scores were calculated for each feature based on the mean and standard deviation of COVID-19-negative samples, and visualized as heatmaps and/or modified sina plots using the ComplexHeatmap (v2.4 .2) (Gu et al., 2016) , ggplot2 (v3.3.1), and ggforce (v0.3.1) packages (Pedersen, 2019) . J o u r n a l P r e -p r o o f 

Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation

HTSeq--a Python framework to work with highthroughput sequencing data

COVID-19 update: Covid-19-associated coagulopathy

Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity. iScience

BBMerge -Accurate paired shotgun read merging via overlap

Downregulation of diaphragm electron transport chain and glycolytic enzyme gene expression in sepsis

Kynurenine pathway, NAD(+) synthesis, and mitochondrial function: Targeting tryptophan metabolism to promote longevity and healthspan

Protective Role of Kallistatin in Vascular and Organ Injury

Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis

Normalizing and integrating metabolomics data

Inhibition of tissue kallikrein by protein C inhibitor. Evidence for identity of protein C inhibitor with the kallikrein binding protein

Early septic shock induces loss of oxidative phosphorylation yield plasticity in liver mitochondria

Normalization of mass cytometry data with bead standards

The CD28 signaling pathway regulates glucose metabolism

Seroconversion stages COVID19 into distinct pathophysiological states

A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm

Hepatitis C Virus Downregulates Core Subunits of Oxidative Phosphorylation, Reminiscent of the Warburg Effect in Cancer Cells

Advances in human proteomics at high scale with the SOMAscan proteomics platform

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice

Orchestrating high-throughput genomic analysis with Bioconductor

Kallikrein Cleaves C3 and Activates Complement

Acute-phase proteins: As diagnostic tool

The role of metabolic checkpoint regulators in B cell survival and transformation

Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2

Circulating Extracellular Histones Are Clinically Relevant Mediators of Multiple Organ Injury

Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype

The Sequence Alignment/Map format and SAMtools

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

COVID-19: Complement, Coagulation, and Collateral Damage

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Immunometabolism: From basic mechanisms to translation

The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice

Efficacy matters: broadening complement inhibition in COVID-19

Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor

Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets

Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages

Neutrophil to lymphocyte ratio and C

Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients

High-Throughput Metabolomics: Isocratic and Gradient Mass Spectrometry-Based Methods

Neutrophil extracellular traps in immunity and disease

ggforce: Accelerating 'ggplot2

The PRIDE database and related tools and resources in 2019: improving support for quantification data

R: A Language and Environment for Statistical Computing

Serpins in thrombosis, hemostasis and fibrinolysis

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease the United States: cohort study

Complement-targeted therapeutics

RStudio: Integrated Development for R

The Yin and Yang of Alarmins in Regulation of Acute Kidney Injury

Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets

Minimizing Batch Effects in Mass Cytometry Data

2020. C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19

The facilitative glucose transporter GLUT3: 20 years of distinction

The multi-functional serpin, protein C inhibitor: beyond thrombosis and hemostasis

Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha

COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status

A systematic evaluation of normalization methods in quantitative label-free proteomics

Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19

Cell-intrinsic metabolic regulation of mononuclear phagocyte activation: Findings from the tip of the iceberg

Metabolite Transporters as Regulators of Immunity

Differential expression of the nuclear-encoded mitochondrial transcriptome in pediatric septic shock

ggplot2: Elegant Graphics for Data Analysis

Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China

Palladium-based mass tag cell barcoding with a doubletfiltering scheme and single-cell deconvolution algorithm

Highlights:  Matched multi-omics datasets are generated for COVID-19 patients and controls  Transcriptome, proteome, metabolome, immune cell maps, and clinical data are linked  An online researcher portal enabling data access and analysis is created  Utility is illustrated by study of biosignatures associated with the biomarker CRP eTOC

describe the development of a multidimensional dataset for the study of COVID-19 known as the COVIDome, which includes diverse clinical, transcriptome, proteome, metabolome, and immune cell datasets. A researcher portal known as the COVIDome Explorer was created to enable global data access and analysis

We are grateful to Dr. Thomas Aaron Issaian for assistance with MS proteomics data analysis. We also thank the SomaLogic team for their support and the Meso Scale Discovery team for generous support with seroconversion assays.We are grateful to Dr. Ian Brooks, Dr. Michelle Edelman and the Health Data Compass Data Warehouse project (healthdatacompass.org) for the clinical data. This work was supported by NIH grants R01AI150305, 3R01AI150305-01S1, UL1TR002535,